Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) in a report released on Friday morning, MarketBeat Ratings reports. They currently have a $8.00 price target on the stock.

Separately, The Goldman Sachs Group upped their price target on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Friday, July 12th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $15.33.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock opened at $4.78 on Friday. Amylyx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $19.95. The firm’s 50 day moving average price is $2.77 and its two-hundred day moving average price is $2.22. The firm has a market cap of $325.07 million, a price-to-earnings ratio of -4.47 and a beta of -0.55.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, August 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The company had revenue of ($1.02) million for the quarter, compared to analysts’ expectations of $18.83 million. During the same period in the prior year, the company earned $0.31 earnings per share. As a group, equities analysts predict that Amylyx Pharmaceuticals will post -2.27 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director George M. Milne, Jr. bought 100,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were bought at an average cost of $2.20 per share, with a total value of $220,000.00. Following the transaction, the director now directly owns 858,571 shares in the company, valued at approximately $1,888,856.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Justin B. Klee sold 18,589 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $3.20, for a total transaction of $59,484.80. Following the completion of the sale, the chief executive officer now owns 3,120,569 shares in the company, valued at $9,985,820.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director George M. Milne, Jr. bought 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were acquired at an average price of $2.20 per share, with a total value of $220,000.00. Following the purchase, the director now owns 858,571 shares in the company, valued at $1,888,856.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 11.70% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC lifted its position in shares of Amylyx Pharmaceuticals by 52,575.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock worth $43,000 after acquiring an additional 15,247 shares during the period. Algert Global LLC bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $47,000. CWM LLC lifted its position in shares of Amylyx Pharmaceuticals by 104.2% in the 2nd quarter. CWM LLC now owns 28,643 shares of the company’s stock worth $54,000 after acquiring an additional 14,613 shares during the period. SG Americas Securities LLC lifted its position in shares of Amylyx Pharmaceuticals by 113.6% in the 2nd quarter. SG Americas Securities LLC now owns 55,836 shares of the company’s stock worth $106,000 after acquiring an additional 29,697 shares during the period. Finally, Hsbc Holdings PLC lifted its position in shares of Amylyx Pharmaceuticals by 57.9% in the 2nd quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock worth $150,000 after acquiring an additional 27,954 shares during the period. Institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.